complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Published (Last):||17 November 2015|
|PDF File Size:||15.36 Mb|
|ePub File Size:||3.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
doxorrrubicina An increased incidence of ventricular dysfunction and congestive heart failure has been associated with the concurrent use of trastuzumab with anthracyclines e.
Oncology Huntingt ;12 1 Suppl 1: Epirubicin has a triphasic clearance with half-lives for the alpha, beta, and terminal phases of 3 minutes, 1 hour, and 30 hours, respectively. Doxorrhbicina prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin.
Clinicians should consult the appropriate references to verify the dose.
Doxorrubicina – Viquipèdia, l’enciclopèdia lliure
Epirubicin was granted orphan drug status for the treatment of breast cancer prior to approval in the United States. J Clin Oncol ;6: Both cardiac and malignant cells are rich in mitochondria.
Regrowth of hair usually resumes 3 weeks after therapy has been discontinued. Additionally, the free radicals crosslink sulfhydryl groups of calcium-release channels and inhibit Ca-ATPase which leads to extensive depletion of sarcoplasmic reticulum SR calcium stores and prevents restoration of calcium stores in the SR, respectively.
Epirubicin is a vesicant, and administration into soft tissue can cause pain, burning, tissue necrosis and skin ulcer. Attempt to aspirate the drug prior to removing the needle. The FDA approved epirubicin for the adjuvant treatment of node-positive breast cancer in September Following intravenous administration, epirubicin is widely distributed into tissues.
Because antineoplastic agents exert their toxic effects against rapidly growing cells, such as hematopoietic progenitor cells, sargramostim, GM-CSF, and filgrastim, G-CSF, are contraindicated for use in patients within 24 hours of treatment with antineoplastic agents. Epirubicin is rapidly and extensively metabolized by the liver and other tissues, including red blood cells.
There was a problem providing the content you requested
Valspodar is an investigational cyclosporine analog with less renal and immunosuppressive effects than cyclosporine while retaining dodorrubicina on MDR. Women of childbearing potential should be warned against getting pregnant. Tumor lysis syndrome may occur due to treatment with epirubicin; appropriate measures e.
However, later events several months to years after ending mecanimo have been reported. This reaction causes erythema, exfoliative dermatitis, pain, and burning, similar to that experienced with the original radiation therapy. These agents could enhance epirubicin’s activity.
Epirubicin-induced cardiomyopathy and congestive heart failure CHF is associated with the cumulative dose of epirubicin. Anaphylactoid reactions and urticaria may occur following epirubicin administration. Standard- and high-dose etoposide, ifosfamide, carboplatin, and etoposide in patients with small-cell lung cancer: Delayed emesis usually does not occur with epirubicin.
Cyclosporine can be given to block MDR resistance in doses much higher than those used in transplantation. Patients should be monitored carefully for any injection site reaction, especially severe pain, swelling and poor blood return.
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: This may manifest as reduced LVEF, tachycardia, dyspnea, pulmonary edema, hepatomegaly, ascites, pleural effusion, or gallop rhythm. These reactions are associated with excessively rapid administration and do not contraindicate further use. Epirubicin may also form complexes with iron or copper. This may compromise the efficacy of the uricosuric agents probenecid and sulfinpyrazone.
Patients who have received prior mitoxantrone therapy may also experience increased cardiotoxicity. Studies examining the use of the r-isomer of verapamil to block MDR, which has less cardiac effects, are underway. Despite these dose increases, the immune response may still be suboptimal.
Passive immunoprophylaxis with immune globulins may be indicated for immunocompromised persons instead of, or in addition to, vaccination. Other mechanisms of resistance include changes in topoisomerase II and glutathione activity.
Concurrent use of epirubicin with other agents that cause bone marrow or immune suppression such as other antineoplastic agents or immunosuppressives may result in additive effects. Those undergoing chemotherapy should not be exposed to others who have recently received the oral poliovirus vaccine OPV.
Epirubicin has a similar spectrum of activity and toxicity as doxorubicin. Acute cardiotoxicity can medanismo during administration of epirubicin; a cumulative, dose-dependent cardiomyopathy may also occur.